Anyone comparing options here runs into the same obstacle within about ten minutes: the question of how much does ketamine therapy cost? a complete breakdown looks straightforward until you try to answer it with real numbers. This guide sets out what is actually established, what varies between providers, and what to establish before committing to anything, written as continuous explanation rather than a checklist, because the reasoning is what transfers to your own situation.
For anyone weighing options in the United States, a clinic that agrees to treat anyone who asks, without reference to what has already been tried, has replaced clinical judgement with a booking system. Applied to the United States, the point is this: uncontrolled hypertension is treated as a serious caution for a straightforward physiological reason, and a programme that does not check blood pressure before dosing has skipped a step. Weight-based dosing in the region of 0.5 milligrams per kilogram over roughly forty minutes is the convention, though clinics vary in whether they adjust it between sessions. Nothing about the United States changes that. The clinics that treat this as a psychiatric treatment rather than a procedure tend to build psychological support into the protocol rather than offering it as an upsell. Patients researching the United States providers run into this constantly. What people looking at the United States providers usually want is the operational detail, and that is precisely what clinic marketing tends to omit.
Set aside the United States for a moment, because the general position comes first. The mechanism is where ketamine departs from the antidepressants most people have already tried. Conventional selective serotonin reuptake inhibitors work primarily on monoamine systems and typically need four to six weeks before any effect is assessable. Ketamine acts on the glutamate system, principally as an antagonist at the N-methyl-D-aspartate receptor, and the downstream cascade it appears to trigger involves a surge in brain-derived neurotrophic factor and a measurable increase in synaptic connections in regions associated with mood regulation. Researchers describe this as a window of heightened neuroplasticity. The clinically useful framing is that ketamine may open a period during which the brain is more amenable to change, which is precisely why the therapeutic work done around the infusion matters as much as the infusion.
What to do next
A clinic willing to escalate frequency on request, or to supply product without meaningful assessment, has removed the safeguards that keep the risk manageable. Ketamine work sits between psychiatric assessment and sedation management, and clinicians arrive at it from either side with correspondingly different instincts. The the United States listings on this page are organised so that this is checkable rather than assumed. Asking for an annualised cost rather than a per-session figure produces a far more useful number and occasionally a revealing pause. Integration, the structured work of making sense of a session afterwards, is the element most often missing from purely procedural clinics. Travel time belongs in the treatment plan rather than being treated as a detail to solve later. That is as true in the United States as anywhere else in the country. A dose calculated against body weight and adjusted across a course reflects a different philosophy from one held constant regardless of what the previous session produced.
Esketamine, marketed as Spravato, occupies a different regulatory position that is routinely blurred in advertising. It is the S-enantiomer of ketamine, delivered as a nasal spray, and the FDA approved it in 2019 for treatment-resistant depression in adults used alongside an oral antidepressant, then in 2020 for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behaviour. Because it carries a Risk Evaluation and Mitigation Strategy, it can only be given at certified treatment centres, the patient must be observed for at least two hours afterwards, and they cannot drive until the following day. That is the entire practical difference for most people: esketamine is approved, insurable more often than not, and inconvenient; generic intravenous ketamine is off-label, usually paid out of pocket, and more flexible in how it is dosed.
What varies between providers and why it matters
The open question in the field is durability, which is why the maintenance conversation belongs in the first consultation rather than the seventh week. Anyone comparing the United States programmes will find this decisive: the gap between anaesthetic and psychiatric dosing is large enough that describing them as the same treatment obscures more than it explains. The mechanism matters practically because it implies the days after a session may be unusually receptive to therapeutic work. It is the first thing to establish about any the United States programme. Pairing sessions with structured psychological support follows directly from the mechanism, which makes its absence a substantive gap rather than a stylistic one. A history of psychosis or a bipolar diagnosis changes the risk calculation substantially, which is why a thorough intake asks about family psychiatric history and not only personal history.
It is worth pausing on the underlying medicine before returning to the United States. Screening is where a careful programme distinguishes itself, and it happens before anyone discusses scheduling. A thorough intake covers cardiovascular history, because of the blood pressure response; personal and family history of psychosis or bipolar disorder, because of the risk of precipitating an episode; hepatic function, because the liver metabolises the drug; substance use history; current medications and their interactions; and pregnancy status. It should also establish what has already been tried and at what dose, since the term treatment-resistant carries a specific meaning that only applies after adequate trials of at least two antidepressants. A consultation that skips most of this and moves quickly to a package price is telling you something about how the clinic is run.
Why this question is harder than it should be
That holds in the United States as it does everywhere: ketamine is a Schedule III controlled substance, which formally recognises a potential for misuse and shapes how responsible programmes are structured. The practical difference is that esketamine is approved and more often insurable but less flexible, while intravenous ketamine is off-label, usually self-funded and more adjustable. Telehealth has a legitimate role here for consultation, screening, follow-up and integration therapy, and it materially improves access for people far from a metropolitan clinic. It is worth carrying that into every conversation with a the United States provider. Read against the the United States market, continuous monitoring of blood pressure, heart rate and oxygen saturation is the baseline, because subanaesthetic dosing reliably produces a modest rise in the first two. The clinicians running these programmes come from anaesthesiology, psychiatry, emergency medicine and pain management, and the route shapes how the treatment is framed. In the United States the same rule applies: dissociation is the effect people ask about most: a sense of distance from the body, altered time perception and sometimes visual distortion, typically peaking partway through and resolving within half an hour of the infusion ending.
Before comparing anything specific to the United States, the underlying clinical picture is worth stating properly. Ketamine is a Schedule III controlled substance in the United States, and that legal status shapes the entire delivery landscape. It means the drug carries a recognised potential for misuse and dependence. Legitimate programmes respond to that with structural safeguards rather than reassurance: doses administered on site and observed, no take-home supply of injectable product, defined session intervals, and screening that takes substance use history seriously rather than treating it as a formality. A programme willing to escalate frequency on request, or to ship product without meaningful assessment, has removed the guardrails that make the risk manageable.
How the pieces fit together in practice
Anyone comparing the United States programmes will find this decisive: the population the trial evidence covers is narrower than the advertising implies, concentrating on adults who have not responded to at least two adequate antidepressant trials. Monitoring during administration is not a formality, and the difference between continuous and intermittent observation is a reasonable thing to ask about directly. It is the first thing to establish about any the United States programme. A single infusion in the United States commonly falls between four hundred and eight hundred dollars, putting a six-session induction somewhere near two and a half to five thousand. For anyone weighing options in the United States, asking whether integration support is included, who provides it and whether it costs extra separates two quite different models of care within a single phone call. Screening should cover cardiovascular history, personal and family history of psychosis or bipolar disorder, hepatic function, substance use history and current medications. Provider backgrounds in this field vary more than in almost any other corner of medicine, which is why credentials repay a closer reading than usual. It is worth carrying that into every conversation with a the United States provider.
Ketamine has been in continuous clinical use since the United States Food and Drug Administration approved it as a general anaesthetic in 1970, which makes it one of the better characterised drugs in modern medicine from a safety standpoint. What is new is not the molecule but the dose and the intention behind it. Anaesthetic dosing renders a person unconscious for surgery; the subanaesthetic dosing used in mood work is a fraction of that, typically calculated at around 0.5 milligrams per kilogram of body weight delivered slowly over roughly forty minutes. At that level the person stays awake, breathing on their own, able to speak and to signal discomfort. The half century of anaesthetic safety data is genuinely reassuring about the drug itself, and it is also not the same thing as long-term safety data for repeated low-dose psychiatric use, which is a younger and thinner body of evidence.
Making the decision with the information available
Legitimate programmes respond to the abuse potential with structure rather than reassurance: observed administration, no take-home injectable supply and defined session intervals. Anyone searching for treatment in the United States meets the same wall of interchangeable clinic websites, all promising personalised care and none explaining what that means operationally. Resuscitation equipment on site and a clinician credentialed to manage sedation are the structural elements that make the treatment defensible outside a research setting. That is as true in the United States as anywhere else in the country. That holds in the United States as it does everywhere: someone who has not yet tried a first-line treatment is usually better served starting there, where the evidence is stronger, the cost lower and the risk profile better understood. Read against the the United States market, where the evidence is strongest concerns short courses in adults who have not responded to at least two adequate antidepressant trials. In the United States the same rule applies: commercial insurance seldom reimburses off-label intravenous administration, though the associated psychiatric evaluation is sometimes billable and worth asking about specifically.
None of the the United States detail on this page makes sense without the clinical context behind it. Integration is the term the field uses for the work of making sense of what happened, and it is the element most likely to be missing from a purely procedural clinic. The neuroplasticity hypothesis implies that the days following a session may be unusually receptive to therapeutic change, which suggests that pairing sessions with structured psychological support is not an upsell but a plausible way to use the window. Programmes vary enormously in how seriously they take this: some employ therapists and build integration sessions into the protocol, others hand over a worksheet, and some do nothing at all. Asking directly what integration support is included, and whether it costs extra, separates the two models quickly.
Putting this to use
Dosing for mood indications sits far below anaesthetic levels, typically calculated near 0.5 milligrams per kilogram of body weight and delivered slowly across about forty minutes. Headache, dizziness and several hours of grogginess afterwards are ordinary, and driving is prohibited for the remainder of the day without exception. Appointment timing decides whether a course is compatible with employment, which is why the availability of early or late slots is more consequential than it sounds. The the United States listings on this page are organised so that this is checkable rather than assumed. The relevant question about a provider is not only whether they are licensed but whether their training covers both the psychiatric assessment and the physiological monitoring. Patients researching the United States providers run into this constantly. The difficulty facing someone comparing options in the United States is not a shortage of information but an excess of the promotional kind.
Anyone reading this while unwell deserves a straight answer rather than a sales pitch, and the straight answer is that this is a real option for a specific group of people, with real limits that are worth knowing first.
This page is general information, not medical advice, and no directory can assess whether a treatment is appropriate for an individual. Ketamine is a controlled substance with genuine risks, and its use for mood disorders is off-label apart from esketamine, which holds FDA approval for treatment-resistant depression under a restricted programme. Decisions about treatment should be made with a qualified clinician who knows your full history. If you are in crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988 in the United States, or go to your nearest emergency department.